Table 3.
Most frequent adverse events (≥ 2% of total population)
| Preferred term | Previous oxybutynin ER, N= 218, n (%) | Previous tolterodine ER, N= 279, n (%) | Total, N= 497, n (%) |
|---|---|---|---|
| Any AE(s) | 119 (54.6) | 171 (61.3) | 290 (58.4) |
| Dry mouth | 35 (16.1) | 65 (23.3) | 100 (20.1) |
| Constipation | 24 (11.0) | 46 (16.5) | 70 (14.1) |
| Urinary tract infection | 12 (5.5) | 21 (7.5) | 33 (6.6) |
| Headache | 10 (4.6) | 8 (2.9) | 18 (3.6) |
| Nausea | 5 (2.3) | 11 (3.9) | 16 (3.2) |
| Dyspepsia | 5 (2.3) | 8 (2.9) | 13 (2.6) |
| Dry eye | 2 (0.9) | 9 (3.2) | 11 (2.2) |
| Upper respiratory tract infection | 5 (2.3) | 5 (1.8) | 10 (2.0) |
AEs, adverse events.